Literature DB >> 10725425

Identification of antigenic regions on VP2 of African horsesickness virus serotype 3 by using phage-displayed epitope libraries.

L Bentley1, J Fehrsen, F Jordaan, H Huismans, D H du Plessis.   

Abstract

VP2 is an outer capsid protein of African horsesickness virus (AHSV) and is recognized by serotype-discriminatory neutralizing antibodies. With the objective of locating its antigenic regions, a filamentous phage library was constructed that displayed peptides derived from the fragmentation of a cDNA copy of the gene encoding VP2. Peptides ranging in size from approximately 30 to 100 amino acids were fused with pIII, the attachment protein of the display vector, fUSE2. To ensure maximum diversity, the final library consisted of three sub-libraries. The first utilized enzymatically fragmented DNA encoding only the VP2 gene, the second included plasmid sequences, while the third included a PCR step designed to allow different peptide-encoding sequences to recombine before ligation into the vector. The resulting composite library was subjected to immunoaffinity selection with AHSV-specific polyclonal chicken IgY, polyclonal horse immunoglobulins and a monoclonal antibody (MAb) known to neutralize AHSV. Antigenic peptides were located by sequencing the DNA of phages bound by the antibodies. Most antigenic determinants capable of being mapped by this method were located in the N-terminal half of VP2. Important binding areas were mapped with high resolution by identifying the minimum overlapping areas of the selected peptides. The MAb was also used to screen a random 17-mer epitope library. Sequences that may be part of a discontinuous neutralization epitope were identified. The amino acid sequences of the antigenic regions on VP2 of serotype 3 were compared with corresponding regions on three other serotypes, revealing regions with the potential to discriminate AHSV serotypes serologically.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10725425     DOI: 10.1099/0022-1317-81-4-993

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  10 in total

1.  Structural insight into African horsesickness virus infection.

Authors:  Violeta Manole; Pasi Laurinmäki; Wouter Van Wyngaardt; Christiaan A Potgieter; Isabella M Wright; Gert J Venter; Alberdina A van Dijk; B Trevor Sewell; Sarah J Butcher
Journal:  J Virol       Date:  2012-05-16       Impact factor: 5.103

2.  Importance of M-protein C terminus as substrate antigen for serodetection of equine arteritis virus infection.

Authors:  Célia Jeronimo; Denis Archambault
Journal:  Clin Diagn Lab Immunol       Date:  2002-05

3.  Structural Protein VP2 of African Horse Sickness Virus Is Not Essential for Virus Replication In Vitro.

Authors:  René G P van Gennip; Sandra G P van de Water; Christiaan A Potgieter; Piet A van Rijn
Journal:  J Virol       Date:  2017-01-31       Impact factor: 5.103

4.  The immunogenicity of recombinant vaccines based on modified Vaccinia Ankara (MVA) viruses expressing African horse sickness virus VP2 antigens depends on the levels of expressed VP2 protein delivered to the host.

Authors:  Eva Calvo-Pinilla; Simon Gubbins; Peter Mertens; Javier Ortego; Javier Castillo-Olivares
Journal:  Antiviral Res       Date:  2018-04-18       Impact factor: 5.970

5.  B-cell epitopes of African horse sickness virus serotype 4 recognised by immune horse sera.

Authors:  Evans M Mathebula; Frederika E Faber; Wouter Van Wyngaardt; Antoinette Van Schalkwyk; Alri Pretorius; Jeanni Fehrsen
Journal:  Onderstepoort J Vet Res       Date:  2017-02-24       Impact factor: 1.792

Review 6.  African Horse Sickness: A Review of Current Understanding and Vaccine Development.

Authors:  Susan J Dennis; Ann E Meyers; Inga I Hitzeroth; Edward P Rybicki
Journal:  Viruses       Date:  2019-09-11       Impact factor: 5.048

Review 7.  Random-peptide libraries and antigen-fragment libraries for epitope mapping and the development of vaccines and diagnostics.

Authors:  M B Irving; O Pan; J K Scott
Journal:  Curr Opin Chem Biol       Date:  2001-06       Impact factor: 8.822

Review 8.  Adaptive strategies of African horse sickness virus to facilitate vector transmission.

Authors:  Anthony Wilson; Philip Scott Mellor; Camille Szmaragd; Peter Paul Clement Mertens
Journal:  Vet Res       Date:  2008-12-19       Impact factor: 3.683

9.  A single dose of African horse sickness virus (AHSV) VP2 based vaccines provides complete clinical protection in a mouse model.

Authors:  Mine Aksular; Eva Calvo-Pinilla; Alejandro Marín-López; Javier Ortego; Adam C Chambers; Linda A King; Javier Castillo-Olivares
Journal:  Vaccine       Date:  2018-10-08       Impact factor: 3.641

10.  Antiserum from mice vaccinated with modified vaccinia Ankara virus expressing African horse sickness virus (AHSV) VP2 provides protection when it is administered 48h before, or 48h after challenge.

Authors:  Eva Calvo-Pinilla; Francisco de la Poza; Simon Gubbins; Peter Paul Clement Mertens; Javier Ortego; Javier Castillo-Olivares
Journal:  Antiviral Res       Date:  2015-01-30       Impact factor: 5.970

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.